WO2013024394A1 - Novel reference markers of dabigatran etexilate - Google Patents

Novel reference markers of dabigatran etexilate Download PDF

Info

Publication number
WO2013024394A1
WO2013024394A1 PCT/IB2012/054002 IB2012054002W WO2013024394A1 WO 2013024394 A1 WO2013024394 A1 WO 2013024394A1 IB 2012054002 W IB2012054002 W IB 2012054002W WO 2013024394 A1 WO2013024394 A1 WO 2013024394A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
amino
dabigatran etexilate
sample
ethyl
Prior art date
Application number
PCT/IB2012/054002
Other languages
French (fr)
Inventor
Venkatraman JAYARAMAN
Samir Patel
Samir Mistry
Mukesh Timbadiya
Bhupendra Parmar
Parimal TAMBOLI
Original Assignee
Alembic Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alembic Pharmaceuticals Limited filed Critical Alembic Pharmaceuticals Limited
Publication of WO2013024394A1 publication Critical patent/WO2013024394A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8872—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample impurities

Definitions

  • the present invention deals with a new method of obtaining chemically pure and pharmaceutically acceptable Dabigatran or its pharmaceutical acceptable salt having purity at least about 99 % , wherein the content of Dabigatran impurity is less than 0.03-0.15 % as measured by HPLC.
  • the invention also discloses a method of removing specific impurities that are generated either due to the intrinsic instability of Dabigatran or produced in the process of its preparation.
  • the compound of formula (III) is prepared by a reaction of substance IV with reagent V as shown in Scheme 1.
  • the last stage is a reaction of intermediate VI with hexyl chloroformate producing dabigatran and its transformation to a pharmaceutically acceptable salt; in the case of the above mentioned patent application it is the methanesulfonate.
  • Dabigatran Several methods for the preparation of Dabigatran have been described like any synthetic compound, Dabigatran, or a pharmaceutically-acceptable salt thereof can contain process impurities, unreacted starting materials, chemical derivatives of impurities contained in starting materials, synthetic by-products, and degradation products. It is also known in the art that impurities present in an active pharmaceutical ingredient ('API') may arise from degradation of the API, for example, during storage or during the manufacturing process, including the chemical synthesis.
  • 'API' active pharmaceutical ingredient
  • APIs active pharmaceutical ingredients
  • Impurities introduced during commercial manufacturing processes must be limited to very small amounts and are preferably substantially absent.
  • the ICH Q7A guidance for API manufacturers requires that process impurities be maintained below set limits by specifying the quality of raw materials, controlling process parameters, such as temperature, pressure, time, and stoichiometric ratios, and including purification steps, such as crystallization, distillation, and liquid-liquid extraction, in the manufacturing process.
  • Impurities generally found in pharmaceutically active agents and formulations containing them include residual amounts of synthetic precursors to the active agent, by-products which arise during synthesis of the active agent, residual solvent, isomers of the active agent, contaminants which were present in materials used in the synthesis of the active agent or in the preparation of the pharmaceutical formulation, and unidentified adventitious substances.
  • Other impurities which may appear on storage include substances resulting from degradation of the active agent, for instance by oxidation or hydrolysis.
  • process impurities be maintained below set limits by specifying the quality of raw materials, controlling process parameters, such as temperature, pressure, time, and stoichiometric ratios, and including purification steps, such as crystallization, distillation, and liquid-liquid extraction, in the manufacturing process.
  • an API such as Dabigatran Etexilate, or a pharmaceutically-acceptable salt thereof , it must be analyzed for purity, typically, by HPLC or GC analysis, to determine if it is suitable for continued processing and, ultimately, for use in a pharmaceutical product.
  • the API need not be absolutely pure, as absolute purity is a theoretical ideal that is typically unattainable. Rather, purity standards are set with the intention of ensuring that an API is as free of impurities as possible, and, thus, are as safe as possible for clinical use.
  • 'ICH' International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
  • Impurities in Dabigatran Etexilate includes, but not limited to, unreacted starting materials, by-products of the reaction, products of side reactions, or degradation products are undesirable and, in extreme cases, might even be harmful to a patient being treated with a dosage form containing the API.
  • a method for determining the level of impurities in Dabigatran samples and removing the impurities is a need in the art for a method for determining the level of impurities in Dabigatran samples and removing the impurities.
  • the present object of the invention is to provide Dabigatran impurities like,
  • Ethyl 2- ⁇ [(4-carbamimidoylphenyl) amino] methyl ⁇ -1-methyl-1 H -benzimidazole-5-carboxylate hydrochloride having following formula, Ethyl 2-[( ⁇ 4-[imino(ethoxy) Methyl] phenyl ⁇ amino)methyl]-1-methyl-1 H - benzimidazole-5-carboxylate Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate hydrochloride, Ethyl 2-( ⁇ [4-(ethoxycarbonyl)phenyl] amino ⁇ methyl)-1-methyl-1 H -benzimidazole-5-carboxylate, Ethyl-3-[[[2-[[[(4-carbamoylphenyl) amino]methyl]-1-
  • Yet another object of t he invention is to provide Dabigatran Etexilate salt having purity at least about 99 % with the less content from any of the above mentioned impurities and its salts thereof. Moreover the above impurities having HPLC purity range from less than 0.03- 0.15 % as measured by HPLC.
  • Further object of t he invention is to provide Dabigatran impurity, ethyl 2- ⁇ [(4-carbamimidoylphenyl)amino]methyl ⁇ -1-methyl-1 H -benzimidazole-5-carboxylate hydrochloride used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further object of t he invention is to provide Dabigatran impurity, Ethyl 2-[( ⁇ 4-[imino(ethoxy) Methyl] phenyl ⁇ amino)methyl]-1-methyl-1 H - benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further object of t he invention is to provide Dabigatran impurity, Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]- 1-methyl-1H-benzimidazol-5-yl]carbonyl] pyridine-2-ylamino]propionate hydrochloride used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further object of t he invention is to provide Dabigatran impurity, Ethyl 2-( ⁇ [4-(ethoxycarbonyl)phenyl] amino ⁇ methyl)-1-methyl-1 H -benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further object of t he invention is to provide Dabigatran impurity, Ethyl-3-[[[2-[[(4-carbamoylphenyl) amino]methyl]-1-methyl-1H- benzimidazol-5-yl] carbonyl]pyridine-2-ylamino]propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further object of t he invention is to provide Dabigatran impurity, Ethyl 2- ⁇ [(4-cyanophenyl)amino] methyl ⁇ -1-methyl-1 H -benzimidazole- 5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further object of t he invention is to provide Dabigatran impurity, Ethyl 2- ⁇ [(4-carbamoylphenyl) amino]methyl ⁇ -1-methyl-1 H -benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further object of t he invention is to provide Dabigatran impurity, N-(pyridine-2-yl)-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol-5-yl] carbonyl]pyridine-2-ylamino] propionamide used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further object of t he invention is to provide Dabigatran impurity, Methyl-3-[[[2-[[(4-[imino(ethoxy)methyl]phenyl)amino]methyl]-1-methyl-1H- benzimidazol -5-yl] carbonyl]pyridine-2-ylamino]propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further object of the invention is to provide Dabigatran impurity, Methyl-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol- 5-yl] carbonyl]pyridine-2-ylamino] propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • the present aspect of the invention is to provide Dabigatran impurities like:
  • Ethyl 2- ⁇ [(4-carbamimidoylphenyl) amino] methyl ⁇ -1-methyl-1 H -benzimidazole-5-carboxylate hydrochloride having following formula, Ethyl 2-[( ⁇ 4-[imino(ethoxy) Methyl] phenyl ⁇ amino)methyl]-1-methyl-1 H - benzimidazole-5-carboxylate, Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate hydrochloride, Ethyl 2-( ⁇ [4-(ethoxycarbonyl)phenyl] amino ⁇ methyl)-1-methyl-1 H -benzimidazole-5-carboxylate, Ethyl-3-[[[2-[[[(4-carbamoylphenyl) amino]methyl]-1
  • Yet another aspect of t he invention is to provide Dabigatran Etexilate salt having purity at least about 99 % with the less content from any of the above mentioned impurities and its salts thereof. Moreover the above impurities having HPLC purity range from less than 0.03- 0.15 % as measured by HPLC.
  • Further aspect of t he invention is to provide Dabigatran impurity, ethyl 2- ⁇ [(4-carbamimidoylphenyl)amino]methyl ⁇ -1-methyl-1 H -benzimidazole-5-carboxylate hydrochloride used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further aspect of t he invention is to provide Dabigatran impurity, Ethyl 2-[( ⁇ 4-[imino(ethoxy) Methyl] phenyl ⁇ amino)methyl]-1-methyl-1 H - benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further aspect of t he invention is to provide Dabigatran impurity, Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]- 1-methyl-1H-benzimidazol-5-yl]carbonyl] pyridine-2-ylamino]propionate hydrochloride used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further aspect of t he invention is to provide Dabigatran impurity, Ethyl 2-( ⁇ [4-(ethoxycarbonyl)phenyl] amino ⁇ methyl)-1-methyl-1 H -benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further aspect of t he invention is to provide Dabigatran impurity, Ethyl-3-[[[2-[[(4-carbamoylphenyl) amino]methyl]-1-methyl-1H- benzimidazol-5-yl] carbonyl]pyridine-2-ylamino]propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further aspect of t he invention is to provide Dabigatran impurity, Ethyl 2- ⁇ [(4-cyanophenyl)amino] methyl ⁇ -1-methyl-1 H -benzimidazole- 5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further aspect of t he invention is to provide Dabigatran impurity, Ethyl 2- ⁇ [(4-carbamoylphenyl) amino]methyl ⁇ -1-methyl-1 H -benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further aspect of t he invention is to provide Dabigatran impurity, N-(pyridine-2-yl)-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol-5-yl] carbonyl]pyridine-2-ylamino] propionamide used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further aspect of t he invention is to provide Dabigatran impurity, Methyl-3-[[[2-[[(4-[imino(ethoxy)methyl]phenyl)amino]methyl]-1-methyl-1H- benzimidazol -5-yl] carbonyl]pyridine-2-ylamino]propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further aspect of t he invention is to provide Dabigatran impurity, Methyl-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol- 5-yl] carbonyl]pyridine-2-ylamino] propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • the present embodiment of the invention is to provide Dabigatran impurities like,
  • Ethyl 2- ⁇ [(4-carbamimidoylphenyl) amino] methyl ⁇ -1-methyl-1 H -benzimidazole-5-carboxylate hydrochloride having following formula, Ethyl 2-[( ⁇ 4-[imino(ethoxy) Methyl] phenyl ⁇ amino)methyl]-1-methyl-1 H - benzimidazole-5-carboxylate Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate hydrochloride, Ethyl 2-( ⁇ [4-(ethoxycarbonyl)phenyl] amino ⁇ methyl)-1-methyl-1 H -benzimidazole-5-carboxylate, Ethyl-3-[[[2-[[[(4-carbamoylphenyl) amino]methyl]-1-
  • Yet another embodiment of t he invention is to provide Dabigatran Etexilate salt having purity at least about 99 % with the less content from any of the above mentioned impurities and its salts thereof. Moreover the above impurities having HPLC purity range from less than 0.03- 0.15 % as measured by HPLC.
  • Further embodiment of t he invention is to provide Dabigatran impurity, ethyl 2- ⁇ [(4-carbamimidoylphenyl)amino]methyl ⁇ -1-methyl-1 H -benzimidazole-5-carboxylate hydrochloride used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further embodiment of t he invention is to provide Dabigatran impurity, Ethyl 2-[( ⁇ 4-[imino(ethoxy) Methyl] phenyl ⁇ amino)methyl]-1-methyl-1 H - benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further embodiment of t he invention is to provide Dabigatran impurity, Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]- 1-methyl-1H-benzimidazol-5-yl]carbonyl] pyridine-2-ylamino]propionate hydrochloride used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further embodiment of t he invention is to provide Dabigatran impurity, Ethyl 2-( ⁇ [4-(ethoxycarbonyl)phenyl] amino ⁇ methyl)-1-methyl-1 H -benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further embodiment of t he invention is to provide Dabigatran impurity, Ethyl-3-[[[2-[[(4-carbamoylphenyl) amino]methyl]-1-methyl-1H- benzimidazol-5-yl] carbonyl]pyridine-2-ylamino]propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further embodiment of t he invention is to provide Dabigatran impurity, Ethyl 2- ⁇ [(4-cyanophenyl)amino] methyl ⁇ -1-methyl-1 H -benzimidazole- 5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further embodiment of t he invention is to provide Dabigatran impurity, Ethyl 2- ⁇ [(4-carbamoylphenyl) amino]methyl ⁇ -1-methyl-1 H -benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further embodiment of t he invention is to provide Dabigatran impurity, N-(pyridine-2-yl)-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol-5-yl] carbonyl]pyridine-2-ylamino] propionamide used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further embodiment of t he invention is to provide Dabigatran impurity, Methyl-3-[[[2-[[(4-[imino(ethoxy)methyl]phenyl)amino]methyl]-1-methyl-1H- benzimidazol -5-yl] carbonyl]pyridine-2-ylamino]propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Further embodiment of t he invention is to provide Dabigatran impurity, Methyl-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol- 5-yl] carbonyl]pyridine-2-ylamino] propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
  • Impurities isolated by column chromatography form the process of preparation of Dabigatran process in conversion of cyano to imidiate ester:
  • Impurities isolated by column chromatography form the process of preparation of Dabigatran process in conversion of imidiate ester to amidine:
  • Isopropyl ether was added to the above reaction mass, stirred it for 5-10min. decant supernatant layer, Isopropyl ether was added to it. Again decant supernatant layer, Ethanol was added to the residue to give clear solution. To this solution, was added previously prepared ammonical ethanol (Ammonia gas passed into ethanol) at 15-30°C. The reaction mixture was allowed to stir at r. t. for about 20-24h.
  • reaction mass was filtered and washed with ethanol.
  • the filtrate was distilled under vacuum and residue was purified by column chromatography to isolate impurities:
  • a reversed-phase liquid chromatographic (RP-LC) method for quantifying, by area percent, the amounts of Dabigatran Etexilate mesylate and all impurities, preferably, KSM-I, Stage-IIA, Stage-II, Propionate ester, Methyl Ester, Amidine impurity, Amide Diester, Diester impurity and Etexilate impurity present in a sample of Dabigatran Etexilate mesylate.
  • impurities preferably, KSM-I, Stage-IIA, Stage-II, Propionate ester, Methyl Ester, Amidine impurity, Amide Diester, Diester impurity and Etexilate impurity present in a sample of Dabigatran Etexilate mesylate.
  • an accurate and well-defined stability indicating HPLC method for the determination of Dabigatran Etexilate mesylate in the presence of degradation products.
  • the method for determining the amount of impurities in a Dabigatran Etexilate mesylate sample comprises the steps of:
  • the initial ratio of eluent A and acetonitrile in step-(c) may be continued at the same ratio for 5 minutes then changed linearly to 55:45 (v/v) within 35 minutes followed by same ratio for 5 minutes. Again changed linearly to 30:70 (v/v) within 45 minutes followed by same ratio for 5 minutes. After 3 minutes the initial gradient of 85:15 is for 7 minutes to be conditioned for every analysis.
  • the column temperature may be maintained at about 50°C.
  • Specificity is the ability of the method to measure the analyte response in the presence of its potential impurities and degradation products.
  • the specificity of the LC method for Dabigatran Etexilate mesylate, Intentional degradation was attempted to stress conditions of acid hydrolysis (using 1M HCl), base hydrolysis (using 1M NaOH), and oxidative degradation (using 3.0% H 2 O 2 ), to evaluate the ability of the proposed method to separate Dabigatran Etexilate mesylate from its degradation products.
  • PDA-UV detector was employed.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A new method of obtaining chemically pure and pharmaceutically acceptable Dabigatran Etexilate or its pharmaceutical acceptable salt having purity at least about 99% is provided, wherein the content of Dabigatran Etexilate individual impurity is less than 0.03-0.15% as measured by HPLC. A method of removing specific impurities that are generated either due to the intrinsic instability of Dabigatran Etexilate or in process of its preparation is provided too.

Description

NOVEL REFERENCE MARKERS OF DABIGATRAN FIELD OF THE INVENTION
The present invention deals with a new method of obtaining chemically pure and pharmaceutically acceptable Dabigatran or its pharmaceutical acceptable salt having purity at least about 99 % , wherein the content of Dabigatran impurity is less than 0.03-0.15 % as measured by HPLC. The invention also discloses a method of removing specific impurities that are generated either due to the intrinsic instability of Dabigatran or produced in the process of its preparation.
BACKGROUND OF THE INVENTION
Preparation of Dabigatran was first described in the document no. WO 9837075; however, this method brings many technological problems, e.g. very complicated purifying operations, problems with low purity of intermediate products and the resulting low yield and low purity of the final product.
One of the advanced intermediates during the production of dabigatran is the substance of formula (III)
Figure DABI02488-appb-I000001
The compound of formula (III) is prepared by a reaction of substance IV with reagent V as shown in Scheme 1.
Figure DABI02488-appb-I000002
The procedure described in WO 9837075 produces compound III in the form of its base or acetate. Both these products require chromatographic purification, which is very difficult to apply in the industrial scale. This purification method burdens the process economy very much and has a negative impact on the yield.
In the next stage conversion of cyano group to amidate using ethanolic HCl followed by ammonium carbonate to obtain substance of formula (VI). The reaction is shown in Scheme 2.
Figure DABI02488-appb-I000003
The procedure in accordance with WO 9837075 produces substance VI in the monohydro chloride form.
When reproducing the procedure of WO 9837075 we found out, in line with WO 9837075, that compound VI prepared by this method required subsequent chromatographic purification as it was an oily substance with a relatively high content of impurities. We did not manage to find a solvent that would enable purification of this substance by crystallization.
The last stage is a reaction of intermediate VI with hexyl chloroformate producing dabigatran and its transformation to a pharmaceutically acceptable salt; in the case of the above mentioned patent application it is the methanesulfonate.
However, the method in accordance with WO 9837075 does not make it possible to prepare dabigatran with high purity, which is required in the case of a pharmaceutical substance, and in a yield acceptable in the industrial scale. The reason is mainly low purity of the intermediate products, which are moreover produced in forms requiring complicated purification with the use of chromatographic methods.
Several methods for the preparation of Dabigatran have been described like any synthetic compound, Dabigatran, or a pharmaceutically-acceptable salt thereof can contain process impurities, unreacted starting materials, chemical derivatives of impurities contained in starting materials, synthetic by-products, and degradation products. It is also known in the art that impurities present in an active pharmaceutical ingredient ('API') may arise from degradation of the API, for example, during storage or during the manufacturing process, including the chemical synthesis.
It is well known in the art that, for human administration, safety considerations require the establishment, by national and international regulatory authorities, of very low limits for identified, but toxicologically uncharacterized impurities, before an active pharmaceutical ingredient (API) product is commercialized. Typically, these limits are less than about 0.15 percent by weight of each impurity. Limits for unidentified and/or uncharacterized impurities are obviously lower, typically less than 0.1 percent by weight. Specific standards can be applied to certain drugs where a pharmacopoeia monograph has been established for that drug. Typically, for impurities that are present in an amount of greater than 0.1 percent by weight, the impurity should be fully identified and characterized.
Therefore, in the manufacture of active pharmaceutical ingredients (APIs) knowledge of the purity of the API, such as Dabigatran, is required before commercialization, as is the purity of the API in the manufactured formulated pharmaceutical product.
Impurities introduced during commercial manufacturing processes must be limited to very small amounts and are preferably substantially absent. For example, the ICH Q7A guidance for API manufacturers requires that process impurities be maintained below set limits by specifying the quality of raw materials, controlling process parameters, such as temperature, pressure, time, and stoichiometric ratios, and including purification steps, such as crystallization, distillation, and liquid-liquid extraction, in the manufacturing process.
Impurities generally found in pharmaceutically active agents and formulations containing them include residual amounts of synthetic precursors to the active agent, by-products which arise during synthesis of the active agent, residual solvent, isomers of the active agent, contaminants which were present in materials used in the synthesis of the active agent or in the preparation of the pharmaceutical formulation, and unidentified adventitious substances. Other impurities which may appear on storage include substances resulting from degradation of the active agent, for instance by oxidation or hydrolysis. the ICH Q7A guidance for API manufacturers requires that process impurities be maintained below set limits by specifying the quality of raw materials, controlling process parameters, such as temperature, pressure, time, and stoichiometric ratios, and including purification steps, such as crystallization, distillation, and liquid-liquid extraction, in the manufacturing process.
At certain stages during processing of an API, such as Dabigatran Etexilate, or a pharmaceutically-acceptable salt thereof , it must be analyzed for purity, typically, by HPLC or GC analysis, to determine if it is suitable for continued processing and, ultimately, for use in a pharmaceutical product. The API need not be absolutely pure, as absolute purity is a theoretical ideal that is typically unattainable. Rather, purity standards are set with the intention of ensuring that an API is as free of impurities as possible, and, thus, are as safe as possible for clinical use. In the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ('ICH') guidelines recommend that the amounts of unknown impurities be limited to less than 0.1 percent.
As is known by those skilled in the art, the management of process impurities is greatly enhanced by understanding their chemical structures and synthetic pathways, and by identifying the parameters that influence the amount of impurities in the final product.
Impurities in Dabigatran Etexilate includes, but not limited to, unreacted starting materials, by-products of the reaction, products of side reactions, or degradation products are undesirable and, in extreme cases, might even be harmful to a patient being treated with a dosage form containing the API. Thus, there is a need in the art for a method for determining the level of impurities in Dabigatran samples and removing the impurities.
While developing a process for the preparation of Dabigatran Etexilate, present inventors serendipitously found an improved process for the preparation of highly pure Dabigatran which minimizes process impurity like:
  1. Ethyl 2-{[(4-carbamimidoylphenyl) amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride,
  2. Ethyl 2-[({4-[imino(ethoxy) Methyl] phenyl}amino)methyl]-1-methyl-1H- benzimidazole-5-carboxylate,
  3. Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate hydrochloride,
  4. Ethyl 2-({[4-(ethoxycarbonyl)phenyl] amino}methyl)-1-methyl-1H-benzimidazole-5-carboxylate,
  5. Ethyl-3-[[[2-[[(4-carbamoylphenyl) amino]methyl]-1-methyl-1H- benzimidazol-5-yl] carbonyl]pyridine-2-ylamino]propionate,
  6. Ethyl 2-{[(4-cyanophenyl)amino] methyl}-1-methyl-1H-benzimidazole- 5-carboxylate,
  7. Ethyl 2-{[(4-carbamoylphenyl) amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate,
  8. N-(pyridine-2-yl)-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol-5-yl] carbonyl]pyridine-2-ylamino] propionamide,
  9. Methyl-3-[[[2-[[(4-[imino(ethoxy)methyl]phenyl)amino]methyl]-1-methyl-1H- benzimidazol -5-yl] carbonyl]pyridine-2-ylamino]propionate
  10. Methyl-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol- 5-yl] carbonyl]pyridine-2-ylamino] propionate.
OBJECT OF THE INVENTION
The present object of the invention is to provide Dabigatran impurities like,
Ethyl 2-{[(4-carbamimidoylphenyl) amino] methyl}-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride, having following formula,
Figure DABI02488-appb-I000004
Ethyl 2-[({4-[imino(ethoxy) Methyl] phenyl}amino)methyl]-1-methyl-1H- benzimidazole-5-carboxylate
Figure DABI02488-appb-I000005
Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate hydrochloride,
Figure DABI02488-appb-I000006
Ethyl 2-({[4-(ethoxycarbonyl)phenyl] amino}methyl)-1-methyl-1H-benzimidazole-5-carboxylate,
Figure DABI02488-appb-I000007
Ethyl-3-[[[2-[[(4-carbamoylphenyl) amino]methyl]-1-methyl-1H- benzimidazol-5-yl] carbonyl]pyridine-2-ylamino]propionate,
Figure DABI02488-appb-I000008
Ethyl 2-{[(4-cyanophenyl)amino] methyl}-1-methyl-1H-benzimidazole- 5-carboxylate,
Figure DABI02488-appb-I000009
Ethyl 2-{[(4-carbamoylphenyl) amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate,
Figure DABI02488-appb-I000010
N-(pyridine-2-yl)-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol-5-yl] carbonyl]pyridine-2-ylamino] propionamide,
Figure DABI02488-appb-I000011
Methyl-3-[[[2-[[(4-[imino(ethoxy)methyl]phenyl)amino]methyl]-1-methyl-1H- benzimidazol -5-yl] carbonyl]pyridine-2-ylamino]propionate
Figure DABI02488-appb-I000012
Methyl-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol- 5-yl] carbonyl]pyridine-2-ylamino] propionate
Figure DABI02488-appb-I000013
Yet another object of t he invention is to provide Dabigatran Etexilate salt having purity at least about 99 % with the less content from any of the above mentioned impurities and its salts thereof. Moreover the above impurities having HPLC purity range from less than 0.03- 0.15 % as measured by HPLC.
Further object of t he invention is to provide Dabigatran impurity, ethyl 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further object of t he invention is to provide Dabigatran impurity, Ethyl 2-[({4-[imino(ethoxy) Methyl] phenyl}amino)methyl]-1-methyl-1H- benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further object of t he invention is to provide Dabigatran impurity, Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]- 1-methyl-1H-benzimidazol-5-yl]carbonyl] pyridine-2-ylamino]propionate hydrochloride used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further object of t he invention is to provide Dabigatran impurity, Ethyl 2-({[4-(ethoxycarbonyl)phenyl] amino}methyl)-1-methyl-1H-benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further object of t he invention is to provide Dabigatran impurity, Ethyl-3-[[[2-[[(4-carbamoylphenyl) amino]methyl]-1-methyl-1H- benzimidazol-5-yl] carbonyl]pyridine-2-ylamino]propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further object of t he invention is to provide Dabigatran impurity, Ethyl 2-{[(4-cyanophenyl)amino] methyl}-1-methyl-1H-benzimidazole- 5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further object of t he invention is to provide Dabigatran impurity, Ethyl 2-{[(4-carbamoylphenyl) amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further object of t he invention is to provide Dabigatran impurity, N-(pyridine-2-yl)-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol-5-yl] carbonyl]pyridine-2-ylamino] propionamide used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further object of t he invention is to provide Dabigatran impurity, Methyl-3-[[[2-[[(4-[imino(ethoxy)methyl]phenyl)amino]methyl]-1-methyl-1H- benzimidazol -5-yl] carbonyl]pyridine-2-ylamino]propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further object of the invention is to provide Dabigatran impurity, Methyl-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol- 5-yl] carbonyl]pyridine-2-ylamino] propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
SUMMARY OF THE INVENTION
The present aspect of the invention is to provide Dabigatran impurities like:
Ethyl 2-{[(4-carbamimidoylphenyl) amino] methyl}-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride, having following formula,
Figure DABI02488-appb-I000004
Ethyl 2-[({4-[imino(ethoxy) Methyl] phenyl}amino)methyl]-1-methyl-1H- benzimidazole-5-carboxylate,
Figure DABI02488-appb-I000005
Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate hydrochloride,
Figure DABI02488-appb-I000006
Ethyl 2-({[4-(ethoxycarbonyl)phenyl] amino}methyl)-1-methyl-1H-benzimidazole-5-carboxylate,
Figure DABI02488-appb-I000007
Ethyl-3-[[[2-[[(4-carbamoylphenyl) amino]methyl]-1-methyl-1H- benzimidazol-5-yl] carbonyl]pyridine-2-ylamino]propionate,
Figure DABI02488-appb-I000008
Ethyl 2-{[(4-cyanophenyl)amino] methyl}-1-methyl-1H-benzimidazole- 5-carboxylate,
Figure DABI02488-appb-I000009
Ethyl 2-{[(4-carbamoylphenyl) amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate,
Figure DABI02488-appb-I000010
N-(pyridine-2-yl)-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol-5-yl] carbonyl]pyridine-2-ylamino] propionamide,
Figure DABI02488-appb-I000011
Methyl-3-[[[2-[[(4-[imino(ethoxy)methyl]phenyl)amino]methyl]-1-methyl-1H- benzimidazol -5-yl] carbonyl]pyridine-2-ylamino]propionate,
Figure DABI02488-appb-I000012
Methyl-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol- 5-yl] carbonyl]pyridine-2-ylamino] propionate,
Figure DABI02488-appb-I000013
Yet another aspect of t he invention is to provide Dabigatran Etexilate salt having purity at least about 99 % with the less content from any of the above mentioned impurities and its salts thereof. Moreover the above impurities having HPLC purity range from less than 0.03- 0.15 % as measured by HPLC.
Further aspect of t he invention is to provide Dabigatran impurity, ethyl 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further aspect of t he invention is to provide Dabigatran impurity, Ethyl 2-[({4-[imino(ethoxy) Methyl] phenyl}amino)methyl]-1-methyl-1H- benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further aspect of t he invention is to provide Dabigatran impurity, Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]- 1-methyl-1H-benzimidazol-5-yl]carbonyl] pyridine-2-ylamino]propionate hydrochloride used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further aspect of t he invention is to provide Dabigatran impurity, Ethyl 2-({[4-(ethoxycarbonyl)phenyl] amino}methyl)-1-methyl-1H-benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further aspect of t he invention is to provide Dabigatran impurity, Ethyl-3-[[[2-[[(4-carbamoylphenyl) amino]methyl]-1-methyl-1H- benzimidazol-5-yl] carbonyl]pyridine-2-ylamino]propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further aspect of t he invention is to provide Dabigatran impurity, Ethyl 2-{[(4-cyanophenyl)amino] methyl}-1-methyl-1H-benzimidazole- 5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further aspect of t he invention is to provide Dabigatran impurity, Ethyl 2-{[(4-carbamoylphenyl) amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further aspect of t he invention is to provide Dabigatran impurity, N-(pyridine-2-yl)-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol-5-yl] carbonyl]pyridine-2-ylamino] propionamide used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further aspect of t he invention is to provide Dabigatran impurity, Methyl-3-[[[2-[[(4-[imino(ethoxy)methyl]phenyl)amino]methyl]-1-methyl-1H- benzimidazol -5-yl] carbonyl]pyridine-2-ylamino]propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further aspect of t he invention is to provide Dabigatran impurity, Methyl-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol- 5-yl] carbonyl]pyridine-2-ylamino] propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
DETAILS DESCRIPTION OF THE INVENTION
The present embodiment of the invention is to provide Dabigatran impurities like,
Ethyl 2-{[(4-carbamimidoylphenyl) amino] methyl}-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride, having following formula,
Figure DABI02488-appb-I000004
Ethyl 2-[({4-[imino(ethoxy) Methyl] phenyl}amino)methyl]-1-methyl-1H- benzimidazole-5-carboxylate
Figure DABI02488-appb-I000005
Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate hydrochloride,
Figure DABI02488-appb-I000006
Ethyl 2-({[4-(ethoxycarbonyl)phenyl] amino}methyl)-1-methyl-1H-benzimidazole-5-carboxylate,
Figure DABI02488-appb-I000007
Ethyl-3-[[[2-[[(4-carbamoylphenyl) amino]methyl]-1-methyl-1H- benzimidazol-5-yl] carbonyl]pyridine-2-ylamino]propionate,
Figure DABI02488-appb-I000008
Ethyl 2-{[(4-cyanophenyl)amino] methyl}-1-methyl-1H-benzimidazole- 5-carboxylate,
Figure DABI02488-appb-I000009
Ethyl 2-{[(4-carbamoylphenyl) amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate,
Figure DABI02488-appb-I000010
N-(pyridine-2-yl)-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol-5-yl] carbonyl]pyridine-2-ylamino] propionamide,
Figure DABI02488-appb-I000011
Methyl-3-[[[2-[[(4-[imino(ethoxy)methyl]phenyl)amino]methyl]-1-methyl-1H- benzimidazol -5-yl] carbonyl]pyridine-2-ylamino]propionate
Figure DABI02488-appb-I000012
Methyl-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol- 5-yl] carbonyl]pyridine-2-ylamino] propionate
Figure DABI02488-appb-I000013
Yet another embodiment of t he invention is to provide Dabigatran Etexilate salt having purity at least about 99 % with the less content from any of the above mentioned impurities and its salts thereof. Moreover the above impurities having HPLC purity range from less than 0.03- 0.15 % as measured by HPLC.
Further embodiment of t he invention is to provide Dabigatran impurity, ethyl 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further embodiment of t he invention is to provide Dabigatran impurity, Ethyl 2-[({4-[imino(ethoxy) Methyl] phenyl}amino)methyl]-1-methyl-1H- benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further embodiment of t he invention is to provide Dabigatran impurity, Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]- 1-methyl-1H-benzimidazol-5-yl]carbonyl] pyridine-2-ylamino]propionate hydrochloride used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further embodiment of t he invention is to provide Dabigatran impurity, Ethyl 2-({[4-(ethoxycarbonyl)phenyl] amino}methyl)-1-methyl-1H-benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further embodiment of t he invention is to provide Dabigatran impurity, Ethyl-3-[[[2-[[(4-carbamoylphenyl) amino]methyl]-1-methyl-1H- benzimidazol-5-yl] carbonyl]pyridine-2-ylamino]propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further embodiment of t he invention is to provide Dabigatran impurity, Ethyl 2-{[(4-cyanophenyl)amino] methyl}-1-methyl-1H-benzimidazole- 5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further embodiment of t he invention is to provide Dabigatran impurity, Ethyl 2-{[(4-carbamoylphenyl) amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further embodiment of t he invention is to provide Dabigatran impurity, N-(pyridine-2-yl)-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol-5-yl] carbonyl]pyridine-2-ylamino] propionamide used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further embodiment of t he invention is to provide Dabigatran impurity, Methyl-3-[[[2-[[(4-[imino(ethoxy)methyl]phenyl)amino]methyl]-1-methyl-1H- benzimidazol -5-yl] carbonyl]pyridine-2-ylamino]propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Further embodiment of t he invention is to provide Dabigatran impurity, Methyl-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol- 5-yl] carbonyl]pyridine-2-ylamino] propionate used as reference marker or reference standard for determining the purity of Dabigatran Etexilate salt.
Impurities isolated by column chromatography form the process of preparation of Dabigatran process in conversion of cyano to imidiate ester:
To the previously prepared saturated solution of HCl in Ethanol (The solution is prepared by passing dry HCl gas to the absolute alcohol), was added a solution of cyano compound in a mixture of Ethanol and Dichloromethane at 15-30°C. After completion of addition, reaction mixture was allowed to stir at 20-30°C for about 6h. After that the reaction was terminated and taken for work up.
Isopropyl ether was added to the above reaction mass, stirred it for 5-10min. decant supernatant layer, Isopropyl ether was added to it. Again decant supernatant layer, potassium carbonate solution (15%) in water was added into reaction mass and extract with ethyl acetate. Distilled out solvent under vacuum and purified by column chromatography to isolate impurities:
  1. Ethyl 2-[({4-[imino(ethoxy)Methyl]phenyl}amino)methyl]-1-methyl-1H-benzimidazole-5-carboxylate
  2. Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate, hydrochloride
  3. Ethyl 2-({[4-(ethoxycarbonyl)phenyl]amino}methyl)-1-methyl-1H-benzimidazole-5-carboxylate
  4. Ethyl 2-{[(4-cyanophenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate
  5. Methyl-3-[[[2-[[(4-[imino(ethoxy)methyl]phenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate
Impurities isolated by column chromatography form the process of preparation of Dabigatran process in conversion of imidiate ester to amidine:
To the previously prepared saturated solution of HCl in Ethanol (The solution is prepared by passing dry HCl gas to the absolute alcohol), was added a solution of cyano compound in a mixture of Ethanol and Dichloromethane at 15-30°C. After completion of addition, reaction mixture was allowed to stir at 20-30°C for about 6h. After that the reaction was terminated and taken for work up.
Isopropyl ether was added to the above reaction mass, stirred it for 5-10min. decant supernatant layer, Isopropyl ether was added to it. Again decant supernatant layer, Ethanol was added to the residue to give clear solution. To this solution, was added previously prepared ammonical ethanol (Ammonia gas passed into ethanol) at 15-30°C. The reaction mixture was allowed to stir at r. t. for about 20-24h.
The reaction mass was filtered and washed with ethanol. The filtrate was distilled under vacuum and residue was purified by column chromatography to isolate impurities:
  1. Ethyl 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride
  2. Ethyl-3-[[[2-[[(4-carbamoylphenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate
  3. Ethyl 2-{[(4-carbamoylphenyl) amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate
  4. N-(pyridine-2-yl)-3-[[[2-[[(4-amidinophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionamide
  5. Methyl-3-[[[2-[[(4-amidinophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate
According to one aspect of the present invention, there is provided a reversed-phase liquid chromatographic (RP-LC) method for quantifying, by area percent, the amounts of Dabigatran Etexilate mesylate and all impurities, preferably, KSM-I, Stage-IIA, Stage-II, Propionate ester, Methyl Ester, Amidine impurity, Amide Diester, Diester impurity and Etexilate impurity present in a sample of Dabigatran Etexilate mesylate.
According to another aspect of the present invention, there is provided a stability indicating analytical method using the samples generated from forced degradation studies.
According to another aspect of the present invention, there is provided an accurate and well-defined stability indicating HPLC method for the determination of Dabigatran Etexilate mesylate in the presence of degradation products.
Preferably, the method for determining the amount of impurities in a Dabigatran Etexilate mesylate sample comprises the steps of:
  1. Combining a Dabigatran Etexilate mesylate sample with eluent A and acetonitrile in the ratio of about 20:30 (v/v) to obtain a solution;
  2. injecting the sample solution into a 150 mm x 4.6 mm, column with 3.5µm μm ZORBAX SB-Phenyl column;
  3. gradient eluting the sample with a mixture of buffer and acetonitrile in the ratio of 85:15 (v/v) initial and progressively increased to 30:70(v/v) in 45 minutes;
  4. Preparing eluent A by dissolving 4.14 g of Sodium dihydrogen phosphate in 1000 ml of water, dissolve and adjust pH = 5.8 with sodium hydroxide solution. Filter it through 0.45 µ membrane filter and degas;
  5. Measuring of the amounts of Dabigatran and each impurity at 225nm wavelength with a UV detector (having an appropriate recording device).
Preferably, the initial ratio of eluent A and acetonitrile in step-(c) may be continued at the same ratio for 5 minutes then changed linearly to 55:45 (v/v) within 35 minutes followed by same ratio for 5 minutes. Again changed linearly to 30:70 (v/v) within 45 minutes followed by same ratio for 5 minutes. After 3 minutes the initial gradient of 85:15 is for 7 minutes to be conditioned for every analysis. The column temperature may be maintained at about 50°C.
Specificity is the ability of the method to measure the analyte response in the presence of its potential impurities and degradation products. The specificity of the LC method for Dabigatran Etexilate mesylate, Intentional degradation was attempted to stress conditions of acid hydrolysis (using 1M HCl), base hydrolysis (using 1M NaOH), and oxidative degradation (using 3.0% H2O2), to evaluate the ability of the proposed method to separate Dabigatran Etexilate mesylate from its degradation products. To check and ensure the homogeneity and purity of Dabigatran peak in the stressed sample solutions, PDA-UV detector was employed.
The present invention is described by the following Example, which is illustrative only and should not be construed so as to limit the scope of the invention in any manner.
Example 1:
Preparation of Ethyl 2-({[4-(ethoxycarbonyl)phenyl]amino}methyl)-1-methyl-1H- benzimidazole-5-carboxylate:
To the previously prepared saturated solution of HCl in Ethanol (The solution is prepared by passing dry HCl gas to the absolute alcohol at ~10-20°C), was added a solution of 1-methyl -2-[N-(4-cyanophenyl)-aminomethyl]benzimidazol-5-yl-carboxylicacid-N-(2-pyridyl)-N-(2-ethoxy carbonyl ethyl)-amide ( cyano compound) in a mixture of Ethanol and Dichloromethane at 15-30°C. After completion of addition, reaction mixture was allowed to stir at 20-30°C for about 6h. After that the reaction was terminated and taken for work up. Isopropyl ether was added to the above reaction mass, stirred it for 5-10min., decant supernatant layer. Isopropyl ether was added to it again and decant supernatant layer. Potassium carbonate solution (15%) in water was added into reaction mass and extracted with ethyl acetate. Solvent was distilled out under vacuum and purified by column chromatography. Eluent was 10% Ethyl acetate in n-Hexane and collect the fraction of impurity. Solvent evaporate at 45°C under vacuum and characterized by mass (M+1=382.5).
Example 2:
Preparation of Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]-1-methyl-1H- benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate, hydrochloride:
To the previously prepared saturated solution of HCl in Ethanol (The solution is prepared by passing dry HCl gas to the absolute alcohol at ~10-20°C), was added a solution of cyano compound in a mixture of Ethanol and Dichloromethane at 15-30°C. After completion of addition, reaction mixture was allowed to stir at 20-30°C for about 6h. After that the reaction was terminated and taken for work up. Isopropyl ether was added to the above reaction mass, stirred it for 5-10min., decant supernatant layer. Isopropyl ether was added to it again and decant supernatant layer. Potassium carbonate solution (15%) in water was added into reaction mass and extracted with ethyl acetate. Solvent was distilled out under vacuum and purified by column chromatography. Eluent was 15% Ethyl acetate in n-Hexane and collect the fraction of impurity. Solvent evaporate at 45°C under vacuum and characterized by mass (M+1=530.5).
Example 3:
Preparation of Ethyl 2-{[(4-cyanophenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate:
To the previously prepared saturated solution of HCl in Ethanol (The solution is prepared by passing dry HCl gas to the absolute alcohol at ~10-20°C), was added a solution of cyano compound in a mixture of Ethanol and Dichloromethane at 15-30°C. After completion of addition, reaction mixture was allowed to stir at 20-30°C for about 6h. After that the reaction was terminated and taken for work up. Isopropyl ether was added to the above reaction mass, stirred it for 5-10min., decant supernatant layer. Isopropyl ether was added to it again and decant supernatant layer. Potassium carbonate solution (15%) in water was added into reaction mass and extracted with ethyl acetate. Solvent was distilled out under vacuum and purified by column chromatography. Eluent was 25% Ethyl acetate in n-Hexane and collect the fraction of impurity. Solvent evaporate at 45°C under vacuum and characterized by mass (M+1=335.4).
Example 4:
Preparation of Ethyl 2-[({4-[imino(ethoxy)Methyl]phenyl}amino)methyl]-1-methyl-1H- benzimidazole-5-carboxylate:
To the previously prepared saturated solution of HCl in Ethanol (The solution is prepared by passing dry HCl gas to the absolute alcohol at ~10-20°C), was added a solution of cyano compound in a mixture of Ethanol and Dichloromethane at 15-30°C. After completion of addition, reaction mixture was allowed to stir at 20-30°C for about 6h. After that the reaction was terminated and taken for work up. Isopropyl ether was added to the above reaction mass, stirred it for 5-10min., decant supernatant layer. Isopropyl ether was added to it again and decant supernatant layer. Potassium carbonate solution (15%) in water was added into reaction mass and extracted with ethyl acetate. Solvent was distilled out under vacuum and purified by column chromatography. Eluent was 40% Ethyl acetate in n-Hexane and collect the fraction of impurity. Solvent evaporate at 45°C under vacuum and characterized by mass (M+1=380.4).
Example 5:
Preparation of Methyl-3-[[[2-[[(4-[imino(ethoxy)methyl]phenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate:
To the previously prepared saturated solution of HCl in Ethanol (The solution is prepared by passing dry HCl gas to the absolute alcohol at ~10-20°C), was added a solution of cyano compound in a mixture of Ethanol and Dichloromethane at 15-30°C. After completion of addition, reaction mixture was allowed to stir at 20-30°C for about 6h. After that the reaction was terminated and taken for work up. Isopropyl ether was added to the above reaction mass, stirred it for 5-10min., decant supernatant layer. Isopropyl ether was added to it again and decant supernatant layer. Potassium carbonate solution (15%) in water was added into reaction mass and extracted with ethyl acetate. Solvent was distilled out under vacuum and purified by column chromatography. Eluent was neat Ethyl acetate and collect the fraction of impurity. Solvent evaporate at 45°C under vacuum and characterized by mass (M+1=514.5).
Example 6:
Preparation of Ethyl 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H- benzimidazole-5-carboxylate hydrochloride:
To the previously prepared saturated solution of HCl in Ethanol (The solution is prepared by passing dry HCl gas to the absolute alcohol at ~10-20°C), was added a solution of cyano compound in a mixture of Ethanol and Dichloromethane at 15-30°C. After completion of addition, reaction mixture was allowed to stir at 20-30°C for about 6h. After that the reaction was terminated and taken for work up. Isopropyl ether was added to the above reaction mass, stirred it for 5-10min. decant supernatant layer, Isopropyl ether was added to it. Again decant supernatant layer, ethanol was added to the residue to give clear solution. To this solution, was added previously prepared ammonical ethanol (Ammonia gas passed into ethanol) at 15-30°C. The reaction mixture was allowed to stir at r. t. for about 20-24h. The reaction mass was filtered and washed with ethanol the filtrate was distilled under vacuum and residue was purified by column chromatography. Eluent was neat Ethyl acetate and collect the fraction of impurity. Solvent evaporate at 48°C under vacuum and characterized by mass (M+1=352.5).
Example 7:
Preparation Methyl-3-[[[2-[[(4-amidinophenyl)amino]methyl]-1-methyl-1H- benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate
To the previously prepared saturated solution of HCl in Ethanol (The solution is prepared by passing dry HCl gas to the absolute alcohol at ~10-20°C), was added a solution of cyano compound in a mixture of Ethanol and Dichloromethane at 15-30°C. After completion of addition, reaction mixture was allowed to stir at 20-30°C for about 6h. After that the reaction was terminated and taken for work up. Isopropyl ether was added to the above reaction mass, stirred it for 5-10min. decant supernatant layer, Isopropyl ether was added to it. Again decant supernatant layer, Ethanol was added to the residue to give clear solution. To this solution, was added previously prepared ammonical ethanol (Ammonia gas passed into ethanol) at 15-30°C. The reaction mixture was allowed to stir at r. t. for about 20-24h. The reaction mass was filtered and washed with ethanol the filtrate was distilled under vacuum and residue was purified by column chromatography. Eluent was neat Ethyl acetate and collect the fraction of impurity. Solvent evaporate at 48°C under vacuum and characterized by mass (M+1=486.5).
Example 8:
Preparation of Ethyl 2-{[(4-carbamoylphenyl) amino]methyl}-1-methyl-1H- benzimidazole-5-carboxylate:
To the previously prepared saturated solution of HCl in Ethanol (The solution is prepared by passing dry HCl gas to the absolute alcohol at ~10-20°C), was added a solution of cyano compound in a mixture of Ethanol and Dichloromethane at 15-30°C. After completion of addition, reaction mixture was allowed to stir at 20-30°C for about 6h. After that the reaction was terminated and taken for work up. Isopropyl ether was added to the above reaction mass, stirred it for 5-10min. decant supernatant layer, Isopropyl ether was added to it. Again decant supernatant layer, Ethanol (5T) was added to the residue to give clear solution. To this solution, was added previously prepared ammonical ethanol (Ammonia gas passed into ethanol) at 15-30°C. The reaction mixture was allowed to stir at r. t. for about 20-24h. The reaction mass was filtered and washed with ethanol the filtrate was distilled under vacuum and residue was purified by column chromatography. Eluent was 5% ethanol in ethyl acetate and collect the fraction of impurity. Solvent evaporate at 48°C under vacuum and characterized by mass (M+1=353.5).
Example 9:
Preparation of Ethyl-3-[[[2-[[(4-carbamoylphenyl)amino]methyl]-1-methyl-1H- benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate
To the previously prepared saturated solution of HCl in Ethanol (The solution is prepared by passing dry HCl gas to the absolute alcohol at ~10-20°C), was added a solution of cyano compound in a mixture of Ethanol and Dichloromethane at 15-30°C. After completion of addition, reaction mixture was allowed to stir at 20-30°C for about 6h. After that the reaction was terminated and taken for work up. Isopropyl ether was added to the above reaction mass, stirred it for 5-10min. decant supernatant layer, Isopropyl ether was added to it. Again decant supernatant layer, Ethanol was added to the residue to give clear solution. To this solution, was added previously prepared ammonical ethanol (Ammonia gas passed into ethanol) at 15-30°C. The reaction mixture was allowed to stir at r. t. for about 20-24h. The reaction mass was filtered and washed with ethanol the filtrate was distilled under vacuum and residue was purified by column chromatography. Eluent was 10% ethanol in ethyl acetate and collect the fraction of impurity. Solvent evaporate at 48°C under vacuum and characterized by mass (M+1=501.6).
Example 10:
Preparation of N-(pyridine-2-yl)-3-[[[2-[[(4-amidinophenyl)amino]methyl]-1-methyl- 1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionamide
To the previously prepared saturated solution of HCl in Ethanol (The solution is prepared by passing dry HCl gas to the absolute alcohol at ~10-20°C), was added a solution of cyano compound in a mixture of Ethanol and Dichloromethane at 15-30°C. After completion of addition, reaction mixture was allowed to stir at 20-30°C for about 6h. After that the reaction was terminated and taken for work up. Isopropyl ether was added to the above reaction mass, stirred it for 5-10min. decant supernatant layer, Isopropyl ether was added to it. Again decant supernatant layer, Ethanol was added to the residue to give clear solution. To this solution, was added previously prepared ammonical ethanol (Ammonia gas passed into ethanol) at 15-30°C. The reaction mixture was allowed to stir at r. t. for about 20-24h. The reaction mass was filtered and washed with ethanol the filtrate was distilled under vacuum and residue was purified by column chromatography. Eluent was 20% ethanol in ethyl acetate and collect the fraction of impurity. Solvent evaporate at 48°C under vacuum and characterized by mass (M+1=548.6).

Claims (25)

  1. [1] A method of testing the purity of a sample of Dabigatran Etexilate or a pharmaceutical dosage form of Dabigatran Etexilate, comprises assaying the said sample for the presence of a compound Ethyl 2-{[(4-carbamimidoylphenyl) amino] methyl}-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride.
  2. [2] A method of testing the purity of a sample of Dabigatran Etexilate or a pharmaceutical dosage form of Dabigatran Etexilate, comprises assaying the said sample for the presence of a compound Ethyl 2-[({4-[imino(ethoxy) Methyl] phenyl}amino)methyl]-1-methyl-1H- benzimidazole-5-carboxylate.
  3. [3] A method of testing the purity of a sample of Dabigatran Etexilate or a pharmaceutical dosage form of Dabigatran Etexilate, comprises assaying the said sample for the presence of a compound Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate hydrochloride.
  4. [4] A method of testing the purity of a sample of Dabigatran Etexilate or a pharmaceutical dosage form of Dabigatran Etexilate, comprises assaying the said sample for the presence of a compoundEthyl 2-({[4-(ethoxycarbonyl)phenyl] amino}methyl)-1-methyl-1H-benzimidazole-5-carboxylate.
  5. [5] A method of testing the purity of a sample of Dabigatran Etexilate or a pharmaceutical dosage form of Dabigatran Etexilate, comprises assaying the said sample for the presence of a compoundEthyl-3-[[[2-[[(4-carbamoylphenyl) amino]methyl]-1-methyl-1H- benzimidazol-5-yl] carbonyl]pyridine-2-ylamino]propionate.
  6. [6] A method of testing the purity of a sample of Dabigatran Etexilate or a pharmaceutical dosage form of Dabigatran Etexilate, comprises assaying the said sample for the presence of a compound Ethyl 2-{[(4-cyanophenyl)amino] methyl}-1-methyl-1H-benzimidazole- 5-carboxylate.
  7. [7] A method of testing the purity of a sample of Dabigatran Etexilate or a pharmaceutical dosage form of Dabigatran Etexilate, comprises assaying the said sample for the presence of a compound Ethyl 2-{[(4-carbamoylphenyl) amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate.
  8. [8] A method of testing the purity of a sample of Dabigatran Etexilate or a pharmaceutical dosage form of Dabigatran Etexilate, comprises assaying the said sample for the presence of a compound N-(pyridine-2-yl)-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol-5-yl] carbonyl]pyridine-2-ylamino] propionamide.
  9. [9] A method of testing the purity of a sample of Dabigatran Etexilate or a pharmaceutical dosage form of Dabigatran Etexilate, comprises assaying the said sample for the presence of a compound Methyl-3-[[[2-[[(4-[imino(ethoxy)methyl]phenyl)amino]methyl]-1-methyl-1H- benzimidazol -5-yl] carbonyl]pyridine-2-ylamino]propionate.
  10. [10] A method of testing the purity of a sample of Dabigatran Etexilate or a pharmaceutical dosage form of Dabigatran Etexilate, comprises assaying the said sample for the presence of a compound Methyl-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol- 5-yl] carbonyl]pyridine-2-ylamino] propionate.
  11. [11] A method of testing the purity of a sample of Dabigatran Etexilate or its salt or a pharmaceutical dosage form comprising Dabigatran Etexilate according to claim 1 to claim 10, which method further comprises using a sample of compound:
    (a) Ethyl 2-{[(4-carbamimidoylphenyl) amino] methyl}-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride , or
    (b) Ethyl 2-[({4-[imino(ethoxy) Methyl] phenyl}amino)methyl]-1-methyl-1H- benzimidazole-5-carboxylate, or
    (c) Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate hydrochloride, or
    (d) Ethyl 2-({[4-(ethoxycarbonyl)phenyl] amino}methyl)-1-methyl-1H-benzimidazole-5-carboxylate, or
    (e) Ethyl-3-[[[2-[[(4-carbamoylphenyl) amino]methyl]-1-methyl-1H- benzimidazol-5-yl] carbonyl]pyridine-2-ylamino]propionate, or
    (f) Ethyl 2-{[(4-cyanophenyl)amino] methyl}-1-methyl-1H-benzimidazole- 5-carboxylate, or
    (g) Ethyl 2-{[(4-carbamoylphenyl) amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate, or
    (h) N-(pyridine-2-yl)-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol-5-yl] carbonyl]pyridine-2-ylamino] propionamide, or
    (i) Methyl-3-[[[2-[[(4-[imino(ethoxy)methyl]phenyl)amino]methyl]-1-methyl-1H- benzimidazol -5-yl] carbonyl]pyridine-2-ylamino]propionate, or
    (j) Methyl-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol- 5-yl] carbonyl]pyridine-2-ylamino] propionate
    having a purity level of at least 80% as a reference marker.
  12. [12] An isolated specific impurity of dabigatran etexilate chemically, Ethyl 2-{[(4-carbamimidoylphenyl) amino] methyl}-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride, having following formula,
    Figure DABI02488-appb-I000004
  13. [13] An isolated specific impurity of dabigatran etexilate chemically, Ethyl 2-[({4-[imino(ethoxy) Methyl] phenyl}amino)methyl]-1-methyl-1H- benzimidazole-5-carboxylate
    Figure DABI02488-appb-I000005
  14. [14] An isolated specific impurity of dabigatran etexilate chemically, Ethyl-3-[[[2-[[(4-(ethoxycarbonyl) phenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate hydrochloride,
    Figure DABI02488-appb-I000006
  15. [15] An isolated specific impurity of dabigatran etexilate chemically, Ethyl 2-({[4-(ethoxycarbonyl)phenyl] amino}methyl)-1-methyl-1H-benzimidazole-5-carboxylate,
    Figure DABI02488-appb-I000007
  16. [16] An isolated specific impurity of dabigatran etexilate chemically, Ethyl-3-[[[2-[[(4-carbamoylphenyl) amino]methyl]-1-methyl-1H- benzimidazol-5-yl] carbonyl]pyridine-2-ylamino]propionate,
    Figure DABI02488-appb-I000008
  17. [17] An isolated specific impurity of dabigatran etexilate chemically, Ethyl 2-{[(4-cyanophenyl)amino] methyl}-1-methyl-1H-benzimidazole- 5-carboxylate,
    Figure DABI02488-appb-I000009
  18. [18] An isolated specific impurity of dabigatran etexilate chemically, Ethyl 2-{[(4-carbamoylphenyl) amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate,
    Figure DABI02488-appb-I000010
  19. [19] An isolated specific impurity of dabigatran etexilate chemically, N-(pyridine-2-yl)-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol-5-yl] carbonyl]pyridine-2-ylamino] propionamide,
    Figure DABI02488-appb-I000011
  20. [20] An isolated specific impurity of dabigatran etexilate chemically, Methyl-3-[[[2-[[(4-[imino(ethoxy)methyl]phenyl)amino]methyl]-1-methyl-1H- benzimidazol -5-yl] carbonyl]pyridine-2-ylamino]propionate,
    Figure DABI02488-appb-I000012
  21. [21] An isolated specific impurity of dabigatran etexilate chemically, Methyl-3-[[[2-[[(4-amidinophenyl)amino] methyl]-1-methyl-1H-benzimidazol- 5-yl] carbonyl]pyridine-2-ylamino] propionate,
    Figure DABI02488-appb-I000013
  22. [22] A Dabigatran Etexilate salt, containing 0.15 % and less of individual impurities of claim 12 to claim 21.
  23. [23] A Dabigatran Etexilate salt having purity at least about 99% wherein impurities of claim 12 to claim 21 in individual is in the range of about 0.03 % to about 0.15 % as measured by HPLC
  24. [24] A process for using reference marker for determining the presence of impurities of in Dabigatran Etexilate or salt comprising the steps of:
    (a) dissolving a reference standard of impurities to produce a reference solution;
    (b) dissolving a sample of Dabigatran Etexilate or salt in a solvent (diluent) to produce a sample solution;
    (c) injecting the diluent, reference solution and sample solution on to an HPLC column, and determining the area of each peak and calculating the purity of Dabigatran Etexilate or salt.
  25. [25] A method for determining the amount of impurities in a Dabigatran Etexilate mesylate sample comprises the steps of:
    (a) Combining a Dabigatran Etexilate mesylate sample with eluent A and acetonitrile in the ratio of about 20:30 (v/v) to obtain a solution;
    (b) injecting the sample solution into a 150 mm x 4.6 mm, column with 3.5µm μm ZORBAX SB-Phenyl column;
    (c) gradient eluting the sample with a mixture of buffer and acetonitrile in the ratio of 85:15 (v/v) initial and progressively increased to 30:70(v/v) in 45 minutes;
    (d) Preparing eluent A by dissolving 4.14 g of Sodium dihydrogen phosphate in 1000 ml of water, dissolve and adjust pH = 5.8 with sodium hydroxide solution. Filter it through 0.45 µ membrane filter and degas;
    (e) Measuring of the amounts of Dabigatran and each impurity at 225nm wavelength with a UV detector.
PCT/IB2012/054002 2011-08-12 2012-08-06 Novel reference markers of dabigatran etexilate WO2013024394A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2292MU2011 2011-08-12
IN2292/MUM/2011 2011-08-12

Publications (1)

Publication Number Publication Date
WO2013024394A1 true WO2013024394A1 (en) 2013-02-21

Family

ID=47714824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/054002 WO2013024394A1 (en) 2011-08-12 2012-08-06 Novel reference markers of dabigatran etexilate

Country Status (1)

Country Link
WO (1) WO2013024394A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014178017A1 (en) * 2013-04-30 2014-11-06 Ranbaxy Laboratories Limited Dabigatran etexilate impurity, process of its preparation, and its use as a reference standard
CN105572275A (en) * 2014-10-08 2016-05-11 华仁药业股份有限公司 Dabigatran etexilate mesylate content detection method

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037075A1 (en) * 1997-02-18 1998-08-27 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, their production and use as medicaments
WO2009018807A1 (en) * 2007-08-06 2009-02-12 Schebo Biotech Ag Novel pharmaceuticals, method for the production thereof, and use thereof in therapy
WO2010045900A1 (en) * 2008-10-24 2010-04-29 Zentiva, K.S. A method for the preparation of dabigatran and its intermediates
CN102050814A (en) * 2009-11-06 2011-05-11 北京美倍他药物研究有限公司 Ester derivatives of dabigatran
CN102050815A (en) * 2009-11-06 2011-05-11 北京美倍他药物研究有限公司 Dabigatran ester derivatives as prodrug

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037075A1 (en) * 1997-02-18 1998-08-27 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, their production and use as medicaments
WO2009018807A1 (en) * 2007-08-06 2009-02-12 Schebo Biotech Ag Novel pharmaceuticals, method for the production thereof, and use thereof in therapy
WO2010045900A1 (en) * 2008-10-24 2010-04-29 Zentiva, K.S. A method for the preparation of dabigatran and its intermediates
CN102050814A (en) * 2009-11-06 2011-05-11 北京美倍他药物研究有限公司 Ester derivatives of dabigatran
CN102050815A (en) * 2009-11-06 2011-05-11 北京美倍他药物研究有限公司 Dabigatran ester derivatives as prodrug

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014178017A1 (en) * 2013-04-30 2014-11-06 Ranbaxy Laboratories Limited Dabigatran etexilate impurity, process of its preparation, and its use as a reference standard
CN105572275A (en) * 2014-10-08 2016-05-11 华仁药业股份有限公司 Dabigatran etexilate mesylate content detection method

Similar Documents

Publication Publication Date Title
KR101103884B1 (en) Heterocyclic fxr binding compounds
CA2798002C (en) Process for the preparation of chiral triazolones
EP1773770B1 (en) Indole-2-carboxamidine derivatives as nmda receptor antagonists
US20080269504A1 (en) Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
CA2268126A1 (en) Quinolines and their therapeutic use
WO2016133317A1 (en) Chiral resolution method of n-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives
WO2006091848A2 (en) Isolated bis-linezolid, preparation thereof, and its use as a reference standard
WO2017119666A1 (en) Chiral resolution method for n-[4-(1-aminoethyl)-phenyl]-sulfonamide derivative using polar aprotic solvent
EP3744713A1 (en) Diyhydropyrimidine-2-one compounds and medicinal uses thereof
WO2013024394A1 (en) Novel reference markers of dabigatran etexilate
MX2007012332A (en) Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard.
WO2013183800A1 (en) Crystalline t-butyl 2-[(4r,6s)-6-formyl-2, 2-dimethyl-1,3-dioxane-4-yl]acetate and preparation method therefor
WO2010110622A2 (en) Novel crystal forms of adefovir dipivoxil and processes for preparing the same
WO2011154860A1 (en) An improved process for preparing iloperidone
WO2014129874A1 (en) Piper amide-based compound as bombesin receptor subtype 3
EP0346207A1 (en) 4-Amino-3-carboxynaphthyridine derivatives, their preparation and pharmaceutical compositions
WO2023068839A1 (en) Film-coated tablet with improved stability containing montelukast or pharmaceutically acceptable salt thereof and levocetirizine or pharmaceutically acceptable salt thereof
KR20030094333A (en) 5-Membered Heterocycles, Preparation and Application Thereof as Medicaments
US20060128737A1 (en) Androgen receptor agonists
WO2016159666A2 (en) Crystal form and preparation method therefor
WO2022220610A1 (en) Method for preparing intermediate for synthesis of sphingosine-1-phosphate receptor agonist
WO2021060691A1 (en) Crystalline form of benzopyranone compound, method for preparing same, and pharmaceutical composition comprising same
TW201813956A (en) Method for preparing phenylalanine compound
WO2018012669A1 (en) Novel mesitylene-cored amphiphiles and uses thereof
WO2020040326A1 (en) Phenylacetic acid derivative, and composition for preventing or treating autoimmune diseases, containing same as active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12823389

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12823389

Country of ref document: EP

Kind code of ref document: A1